Pharmacokinetics and mechanisms of plasma removal of hemoglobin-based oxygen carriers
Source abstract
Abstract
The circulatory persistence, distribution, and metabolism of hemoglobin-based oxygen carriers (HBOCs) is a major determinant of their safety and efficacy. In this communication, published data on the pharmacokinetics and routes of plasma elimination of HBOCs are summarized and evaluated. The circulating half-life of HBOCs is dose-dependent in both animals and humans. Half-life also increases with molecular weight in animals, at least up to the MDa range. The functional half-life of HBOCs is diminished by as much as 40% due to oxidation of the heme group relative to the overall rate of removal of hemoglobin (Hb) from plasma. Kidney excretion of HBOCs is greatly diminished compared to that of unmodified Hb, but the liver remains a primary site of catabolism. Both hepatocytes and Kupffer cells have been implicated in receptor-mediated HBOC uptake. Removal also occurs in the spleen and/or bone marrow and probably at dispersed sites in the endothelium as well. HBOCs extravasate into the lymph at a rate inversely proportional to their molecular weight and are taken up by monocyte/macrophage CD163 receptors, both as free Hb and in complexes with haptoglobin (Hp). The interactions with both Hp and the CD163 receptor are altered by Hb modification. However, monocyte/macrophage uptake may not be a quantitatively important route for the removal of clinically relevant doses of HBOCs. The relative contributions of different removal pathways have yet to be comprehensively determined, particularly in humans.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Neonatal Health and Biochemistry · Heme Oxygenase-1 and Carbon Monoxide
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Chart Biotech Consulting, LLC, Erie, CO, USA
References (100+)
Show source-provided references
1. 10.1161/01.RES.0000255691.76142.4a10.1161/01.RES.0000255691.76142.4a ↗
2. 10.1006/abbi.2001.242610.1006/abbi.2001.2426 ↗
3. 10.1073/pnas.78.11.685810.1073/pnas.78.11.6858 ↗
4. 10.1074/jbc.M110.16484810.1074/jbc.M110.164848 ↗
5. 10.2133/dmpk.24.31810.2133/dmpk.24.318 ↗
6. Anderson PJ, Ning J, Biro GP. 1993. Clearance of differentially labelled infused hemoglobin and polymerized hemoglobin from dog plasma and accumulation in urine and selected tissues. In: Chang TMS, Ed. Blood substitutes and oxygen carriers. New York: Marcel Dekker, pp. 557–563.
7. 10.1093/toxsci/kfs10910.1093/toxsci/kfs109 ↗
8. Baker SL, Dodds EC. 1925. Obstruction of the renal tubules during the excretion of haemoglobin. Brit J Exp Path. 6:247–260.
9. Bakker JC, Berbers GA, Bleeker WK, den Boer PJ, Biessels PT. 1993. Preparation and characterization of crosslinked and polymerized hemoglobin solutions. In: Chang TMS, Ed. Blood substitutes and oxygen carriers. New York: Marcel Dekker, pp. 67–75.
10. Bakker JC, Bleeker WK, van der Plas J. 1986. Properties of hemoglobin interdimerically cross-linked with NFPLP. Prog Clin Biol. 211:49–55.
11. 10.1016/S0021-9258(17)33902-910.1016/S0021-9258(17)33902-9 ↗
12. Berbers GA, Bleeker WK, Stekkinger P, Agterberg J, Rigter G, Bakker JC. 1991. Biophysical characteristics of hemoglobin intramolecularly cross-linked and polymerized. J Lab Clin Med. 117:157–165.
13. 10.1182/blood.V40.6.812.81210.1182/blood.V40.6.812.812 ↗
14. 10.3109/1073119920911971310.3109/10731199209119713 ↗
15. Bleeker WK, van der Plas J, Agterberg J, Rigter G, Bakker JC. 1986. Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5’-phosphate. J Lab Clin Med. 108:448–455.
16. Bleeker WK, van der Plas J, Feitsma RIJ, Agterberg J, Rigter G, De Vries-van Rossen A, et al. 1989. In vivo distribution and elimination of hemoglobin modified by intramolecular cross-linking with 2-nor-2-formylpyridoxal 5’-phosphate. J Lab Clin Med. 113:151–161.
17. 10.3109/1073119950911796210.3109/10731199509117962 ↗
18. 10.1080/1073119060058021510.1080/10731190600580215 ↗
19. Bonhard K, Boysen U. 1982. Preparation of coupled hemoglobin molecules. US Patent. 4336248.
20. 10.3389/fphys.2014.0038510.3389/fphys.2014.00385 ↗
21. 10.1093/intimm/10.9.128910.1093/intimm/10.9.1289 ↗
22. Bouma JM. 1982. Some aspects of plasma protein metabolism as compared with intracellular protein breakdown. Acta Biol Med Ger. 41:53–60.
23. Brooks J. 1932. The oxidation of haemoglobin to methaemoglobin by oxygen. Proc R Soc London B. 109:35–50.10.1098/rspb.1931.0067 ↗
24. 10.1098/rspb.1935.007210.1098/rspb.1935.0072 ↗
25. 10.1016/S0022-2143(96)90006-210.1016/S0022-2143(96)90006-2 ↗
26. 10.1124/jpet.107.12640910.1124/jpet.107.126409 ↗
27. 10.1089/ars.2008.202810.1089/ars.2008.2028 ↗
28. 10.1016/j.biomaterials.2010.01.07210.1016/j.biomaterials.2010.01.072 ↗
29. Bunn HF, Esham WT, Bull RW. 1969. The renal handling of hemoglobin I. Glomerular filtration. J Exp Med. 129:909–924.
30. Bunn HF. 1967. Effect of sulfhydryl reagents on the binding of human hemoglobin to haptoglobin. J Lab Clin Med. 70:606–618.
31. Bunn HF. 1972. Erythrocyte destruction and hemoglobin catabolism. Semin Hematol. 9:3–17.
32. Burhop KE, Doyle MP. 2002. The development and preclinical testing of a second-generation recombinant hemoglobin solution, rHb2.0 for injection. In: Messmer K, Burhop KE, Hutter J, Eds. Microcirculatory effects of hemoglobin solutions. Basel: Karger, pp. 48–64.
33. 10.3109/1073119940911793010.3109/10731199409117930 ↗
34. 10.1097/00003246-200007000-0001710.1097/00003246-200007000-00017 ↗
35. 10.1046/j.1365-3148.2001.00337.x10.1046/j.1365-3148.2001.00337.x ↗
36. 10.1152/ajpheart.2000.278.6.H197410.1152/ajpheart.2000.278.6.H1974 ↗
37. 10.1016/0022-2836(75)90382-410.1016/0022-2836(75)90382-4 ↗
38. 10.1084/jem.2002182910.1084/jem.20021829 ↗
39. Chernoff AI. 1953. Immunologic studies of hemoglobins I. The production of antihemoglobin sera and their immunologic characteristics. Blood. 8:399–412.
40. 10.1124/dmd.107.01917410.1124/dmd.107.019174 ↗
41. 10.1097/MNH.0b013e32832cb96a10.1097/MNH.0b013e32832cb96a ↗
42. 10.1164/ajrccm.158.4.970504210.1164/ajrccm.158.4.9705042 ↗
43. 10.1111/j.1525-1594.1997.tb00250.x10.1111/j.1525-1594.1997.tb00250.x ↗
44. 10.1111/j.1525-1594.1997.tb00444.x10.1111/j.1525-1594.1997.tb00444.x ↗
45. 10.3109/1073119990911768510.3109/10731199909117685 ↗
46. 10.1042/bj193026110.1042/bj1930261 ↗
47. 10.1074/jbc.M60429220010.1074/jbc.M604292200 ↗
48. 10.3109/1073119920911969510.3109/10731199209119695 ↗
49. 10.1016/0022-4804(83)90061-610.1016/0022-4804(83)90061-6 ↗
50. 10.1159/00046529910.1159/000465299 ↗
51. DeVenuto F. 1978. Stability of hemoglobin solution during extended storage. J Lab Clin Med. 92:946–954.
52. 10.3109/1073119920911971410.3109/10731199209119714 ↗
53. 10.1081/BIO-12000272610.1081/BIO-120002726 ↗
54. 10.1016/S0162-0134(00)80291-310.1016/S0162-0134(00)80291-3 ↗
55. 10.1042/BJ2006034110.1042/BJ20060341 ↗
56. 10.1083/jcb.38.1.24410.1083/jcb.38.1.244 ↗
57. 10.1016/j.lfs.2012.08.03610.1016/j.lfs.2012.08.036 ↗
58. 10.1023/A:101106640828310.1023/A:1011066408283 ↗
59. Ericsson JL. 1965a. Transport and digestion of hemoglobin in the proximal tubule I. Light microscopy and cytochemistry of acid phosphatase. Lab Invest. 14:1–15.
60. Ericsson JL. 1965b. Transport and digestion of hemoglobin in the proximal tubule II. Electron microscopy. Lab Invest. 14:16–39.
61. 10.3109/1073119920911968910.3109/10731199209119689 ↗
62. 10.1089/ars.2012.460510.1089/ars.2012.4605 ↗
63. 10.3109/1073119940911788310.3109/10731199409117883 ↗
64. 10.1152/ajpheart.1999.276.2.H76610.1152/ajpheart.1999.276.2.H766 ↗
65. Faivre-Fiorina B, Caron A, Labrude P, Vigneron C. 1998. Les hémoglobines érythrocytaires, plasmatiques et substitutives face aux agents oxydants et réducteurs physiologiques. Ann Biol Clin. 56:545–556.
66. 10.1152/ajpheart.1999.276.6.H219410.1152/ajpheart.1999.276.6.H2194 ↗
67. 10.1177/00045632850220010310.1177/000456328502200103 ↗
68. 10.1073/pnas.86.16.637710.1073/pnas.86.16.6377 ↗
69. Friedman HI, DeVenuto F, Lollini L, Mellick P, Zuck TF. 1978. Morphologic effects following massive exchange transfusions with a stroma-free hemoglobin solution I. Liver . Lab Invest. 39:167–177.
70. 10.1097/00003246-198204000-0001110.1097/00003246-198204000-00011 ↗
71. Gandhi RR, Bell DR. 1992. Importance of charge on transvascular albumin transport in skin and skeletal muscle. Am J Physiol. 262: H999–1008.
72. 10.1016/S0300-9084(00)01191-310.1016/S0300-9084(00)01191-3 ↗
73. 10.1681/ASN.V13242310.1681/ASN.V132423 ↗
74. 10.1002/eji.183026032710.1002/eji.1830260327 ↗
75. 10.1038/ki.1992.25610.1038/ki.1992.256 ↗
76. 10.3109/1073119940911788110.3109/10731199409117881 ↗
77. 10.1083/jcb.44.3.51310.1083/jcb.44.3.513 ↗
78. 10.1016/S1357-2725(01)00144-310.1016/S1357-2725(01)00144-3 ↗
79. Greenburg AG, Maffuid PW. 1983. Modification of hemoglobin – ring opened dials. In: Bolin RB, Geyer RP, Nemo GJ, Eds. Advances in blood substitute research. New York: Alan R Liss. pp. 9–17.
80. 10.1097/00005373-197707000-0000310.1097/00005373-197707000-00003 ↗
81. Greenburg AG. 1983. The effects of hemoglobin on reticulo-endothelial function. In: Bolin RB, Geyer RP, Nemo GJ, Eds. Advances in blood substitute research. New York: Alan R Liss. pp. 127–137.
82. 10.1085/jgp.72.6.76510.1085/jgp.72.6.765 ↗
83. Guyton AC. 1976. Textbook of medical physiology. 5th ed. Philadelphia: WB Saunders.
84. 10.1046/j.1537-2995.2001.41020219.x10.1046/j.1537-2995.2001.41020219.x ↗
85. 10.1111/j.1537-2995.2007.01176.x10.1111/j.1537-2995.2007.01176.x ↗
86. 10.1152/physrev.00055.200610.1152/physrev.00055.2006 ↗
87. 10.1080/1073119000913926510.1080/10731190009139265 ↗
88. 10.1111/j.1365-2141.1976.tb00922.x10.1111/j.1365-2141.1976.tb00922.x ↗
89. Heller P, Yakulis VJ, Josephson AM. 1962. Immunologic studies of human hemoglobins. J Lab Clin Med. 59:401–411.
90. Hershko C, Cook JD, Finch CA. 1972. Storage iron kinetics. II. The uptake of hemoglobin by hepatic parenchymal cells. J Lab Clin Med. 80:624–634.
91. 10.1177/03913988860090031110.1177/039139888600900311 ↗
92. Hess JR, Fadare SO, Tolentino LSL, Bangal NR, Winslow RM. 1989. The intravascular persistence of crosslinked human hemoglobin. In: Brewer GJ, Ed. The red cell: seventh Ann Arbor conference. New York: Alan R. Liss. pp. 351–360.
93. Hsia JC, Song DL, Er SS, Wong LTL, Keipert PE, Gomez CL, et al. 1993. Pharmacokinetic studies in the rat on a o-raffinose polymerized human hemoglobin. In: Chang TMS, Ed. Blood substitutes and oxygen carriers. New York: Marcel Dekker. pp. 383–391.
94. 10.1097/00003246-199605000-0000610.1097/00003246-199605000-00006 ↗
95. Hughes GS, Francom SF, Antal EJ, Adams WJ, Locker PK, Yancey EP, Jacobs EE. 1995. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med. 126:444–451.
96. 10.1046/j.1365-2567.1996.d01-775.x10.1046/j.1365-2567.1996.d01-775.x ↗
97. 10.1136/jcp.s1-6.1.1310.1136/jcp.s1-6.1.13 ↗
98. 10.1371/journal.pone.005984110.1371/journal.pone.0059841 ↗
99. 10.1073/pnas.93.11.551210.1073/pnas.93.11.5512 ↗
100. 10.1182/blood.V26.6.705.70510.1182/blood.V26.6.705.705 ↗